DOBMEIER ERIC 4

What Happened

• Eric Dobmeier, a director of Janux Therapeutics (JANX), reported two awards on 2026-06-11: 5,500 restricted stock units (RSUs) and a 15,500-share derivative award (option). Both were granted at $0.00 (no cash paid). These are company compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
• Grants: 5,500 RSUs (A) at $0.00; 15,500 derivative award (A) at $0.00.
• Vesting: RSUs vest on the earlier of June 11, 2027 or the next annual meeting, subject to continuous service (Footnote F1). The derivative (option) vests in equal monthly installments over the 12 months after June 11, 2026, but will be fully vested by the next annual meeting if service continues (Footnote F2).
• Shares owned after the transaction: not specified in the excerpted filing.
• No immediate sale or cashless exercise reported; these are forward-looking compensation awards.

Context

• Awards like RSUs and time-based options are common director compensation and do not necessarily signal an immediate trading view; they are typically intended for retention/compensation.
• Because no purchase or sale occurred and no cash exchanged, this filing documents grant-based compensation rather than market-driven insider buying or selling.